Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
about
Drug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirOpioid metabolismMolecular characterization of CYP2B6 substratesS-Methadone augments R-methadone induced respiratory depression in the neonatal guinea pig.Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and responseStereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliationFatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic studyChiral toxicology: it's the same thing...only different.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Differences in Methadone Metabolism by CYP2B6 VariantsAssessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and MetabolismPerioperative pharmacokinetics of methadone in adolescents.Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavirMethadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamicsMethadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.Role of cytochrome P4502B6 in methadone metabolism and clearance.Interindividual variability of methadone response: impact of genetic polymorphism.Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor.Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.Methadone: a review of drug-drug and pathophysiological interactions.Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.Pathophysiology and principles of management of the many faces of the acute vaso-occlusive crisis in patients with sickle cell disease.Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response.Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study.Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
P2860
Q28084266-53C35F36-9879-4375-9D6D-58256E317929Q28250437-9E889FFC-FD6E-47B9-84D6-A35F37060F8CQ28282980-567199DD-18A5-4532-8AB8-A60C29044D49Q33806539-4A9C43F5-6733-4B50-9545-FC7507B8A61CQ33833207-1317B81C-22A8-49FD-BF22-2B674A3A56C7Q33903933-67F73BE9-6EE2-40CE-867D-E20E1E3B3622Q34424648-E73F6B6B-7A7B-48E2-A379-0B20F0AE3CB4Q34500741-F6EB9445-4229-4315-B139-4522BF1B4979Q34604652-FA14FB0B-944E-40A7-9875-09CE092142BCQ34626158-7BAA9FFD-BF24-4894-8E08-8BECBBC5E81AQ34979115-50CD7C97-731D-4F30-BDD6-B99F8AA066B4Q35000765-88600EDD-AB01-42EC-B592-D66291C4BF13Q35211432-9C23A755-8DF9-47A6-B162-F1A3AD897EEBQ35745266-7FA83ADA-9EEB-4146-8C98-1DC98A7FB33EQ35960681-F642C544-BF2A-4319-AAD6-C5F990541E11Q35968979-2BCFB848-BF8A-414F-9D2A-A8D85309EE36Q36036200-222743A1-0800-4B6A-B724-1101D6FBA228Q36342286-E3D5C571-8C16-4115-B643-82D223B5E248Q36578070-06CDCC08-3BB1-44D8-B80E-CFBA91705D63Q36593838-D754B1C4-CC36-4F8E-9923-A6A725093E52Q36637864-32901FB7-C13F-4A9B-B297-D9D9F4E1C36EQ36641884-2C80BEFA-4E93-4FFF-8813-C4282B484314Q36652680-C9BF4A7C-C5C5-4145-8AB0-FDBC2BBEF57CQ36693543-DD7B695E-AE6A-4D86-89A5-32DA071D6E41Q36717150-83AB0A46-67B4-4403-8BD4-35049CBFCCFFQ37094439-F7A91ADF-B0DF-4B88-AD27-EC5107489E70Q37142009-D0A60C8E-6FD7-411B-97C8-6700B345270FQ37199426-18EC3DD0-CD40-4898-8D53-50600DD31310Q37311631-85DD13B1-15EB-4CB5-ADB9-2944A3B376B0Q37325606-C755D932-BE7A-417D-9281-6D542B72785AQ37409042-1D799024-FE55-426B-9472-CDA28C3B118AQ37950478-A85F140C-1C58-4857-AB96-7A5B741ABB25Q38184547-7EB7E5DB-FB2B-42A6-ADDA-617AFAA0A892Q38257400-AF8CF56A-663D-428B-8BCF-476E6B8CDE44Q38870014-CD755045-2503-43B3-A8CE-5C175E20F47EQ38921093-F4A401F6-A372-4DAD-8C31-A960CFEBAFB6Q41153557-61628632-54E8-4649-8D72-A117D9EF084DQ42241537-CF92700D-E977-462F-B2B3-C3B2BB190BB1Q42628651-ECB98830-2AA8-4501-99D5-3E74677B7BEFQ42660244-C668F7A0-BA7A-4379-AAF0-CA8EB69D68A3
P2860
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@ast
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@en
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@nl
type
label
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@ast
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@en
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@nl
prefLabel
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@ast
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@en
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@nl
P2093
P356
P1476
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
@en
P2093
Dale Whittington
Evan D Kharasch
Kyle E Allen
Pamela Sheffels
Rheem A Totah
P304
P356
10.1124/JPET.106.117580
P407
P577
2007-01-26T00:00:00Z